Log in

NASDAQ:SRDX - SurModics Stock Price, Forecast & News

-0.33 (-0.88 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
Now: $37.12
50-Day Range
MA: $40.16
52-Week Range
Now: $37.12
Volume61,271 shs
Average Volume72,020 shs
Market Capitalization$504.39 million
P/E Ratio78.98
Dividend YieldN/A
Surmodics, Inc, together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:SRDX



Sales & Book Value

Annual Sales$100.08 million
Cash Flow$1.28 per share
Book Value$9.08 per share


Net Income$7.59 million


Market Cap$504.39 million
Next Earnings Date5/6/2020 (Estimated)

Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.

SurModics (NASDAQ:SRDX) Frequently Asked Questions

What is SurModics' stock symbol?

SurModics trades on the NASDAQ under the ticker symbol "SRDX."

How were SurModics' earnings last quarter?

SurModics, Inc. (NASDAQ:SRDX) released its earnings results on Wednesday, February, 5th. The company reported $0.05 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.13. The company earned $22.62 million during the quarter, compared to analysts' expectations of $22.82 million. SurModics had a net margin of 6.40% and a return on equity of 7.47%. View SurModics' Earnings History.

When is SurModics' next earnings date?

SurModics is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for SurModics.

What guidance has SurModics issued on next quarter's earnings?

SurModics issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, February, 5th. The company provided earnings per share (EPS) guidance of -0.44--0.14 for the period, compared to the Thomson Reuters consensus estimate of $-0.34. The company issued revenue guidance of $87-91 million, compared to the consensus revenue estimate of $89.44 million.

What price target have analysts set for SRDX?

3 equities research analysts have issued twelve-month price targets for SurModics' shares. Their forecasts range from $50.00 to $68.00. On average, they expect SurModics' stock price to reach $58.00 in the next year. This suggests a possible upside of 56.3% from the stock's current price. View Analyst Price Targets for SurModics.

What is the consensus analysts' recommendation for SurModics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SurModics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SurModics.

Has SurModics been receiving favorable news coverage?

Press coverage about SRDX stock has trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. SurModics earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for SurModics.

Are investors shorting SurModics?

SurModics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 790,800 shares, an increase of 12.3% from the January 15th total of 704,000 shares. Based on an average trading volume of 91,700 shares, the days-to-cover ratio is presently 8.6 days. Approximately 6.0% of the shares of the stock are short sold. View SurModics' Current Options Chain.

Who are some of SurModics' key competitors?

What other stocks do shareholders of SurModics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SurModics investors own include Netflix (NFLX), Intel (INTC), NVIDIA (NVDA), Gilead Sciences (GILD), Adobe (ADBE), Exelixis (EXEL), Tandem Diabetes Care (TNDM), Alibaba Group (BABA), Exxon Mobil (XOM) and DexCom (DXCM).

Who are SurModics' key executives?

SurModics' management team includes the folowing people:
  • Mr. Gary R. Maharaj, CEO, Pres & Director (Age 56)
  • Mr. Timothy J. Arens, Chief Financial Officer (Age 52)
  • Mr. Bryan K. Phillips, Sr. VP of Legal, HR & Information Technology, Gen. Counsel and Sec. (Age 48)
  • Mr. Thomas A. Greaney, Chief Operating Officer of Medical Devices (Age 53)
  • Mr. Gregg S. Sutton, VP of R&D - Medical Devices (Age 59)

Who are SurModics' major shareholders?

SurModics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (6.52%), State Street Corp (3.56%), Janus Henderson Group PLC (3.24%), Royce & Associates LP (2.40%), Acadian Asset Management LLC (2.27%) and Geode Capital Management LLC (1.90%). Company insiders that own SurModics stock include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Gregg S Sutton, Jose H Bedoya, Joseph J Stich, Lisa Wipperman Heine, Susan E Knight and Timothy J Arens. View Institutional Ownership Trends for SurModics.

Which major investors are selling SurModics stock?

SRDX stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Renaissance Technologies LLC, Royce & Associates LP, Marshall Wace LLP, Bank of America Corp DE, Connor Clark & Lunn Investment Management Ltd., Arizona State Retirement System and Public Sector Pension Investment Board. Company insiders that have sold SurModics company stock in the last year include Gary R Maharaj, Joseph J Stich and Lisa Wipperman Heine. View Insider Buying and Selling for SurModics.

Which major investors are buying SurModics stock?

SRDX stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Acadian Asset Management LLC, Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., Great West Life Assurance Co. Can, Mairs & Power INC, Sei Investments Co. and Alambic Investment Management L.P.. View Insider Buying and Selling for SurModics.

How do I buy shares of SurModics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SurModics' stock price today?

One share of SRDX stock can currently be purchased for approximately $37.12.

How big of a company is SurModics?

SurModics has a market capitalization of $504.39 million and generates $100.08 million in revenue each year. The company earns $7.59 million in net income (profit) each year or $0.72 on an earnings per share basis. SurModics employs 338 workers across the globe.View Additional Information About SurModics.

What is SurModics' official website?

The official website for SurModics is http://www.surmodics.com/.

How can I contact SurModics?

SurModics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]

MarketBeat Community Rating for SurModics (NASDAQ SRDX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  305 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  591
MarketBeat's community ratings are surveys of what our community members think about SurModics and other stocks. Vote "Outperform" if you believe SRDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: What does RSI mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel